Nominating and Governance Committee
The Nominating Committee oversees recruitment and replacement of Board and Committee members.
Members of the Committee
Janice Bailey has been the Scientific Director of the Fonds de recherche du Québec – Nature and Technologies (FRQNT) since 2019. The mandate of the FRQNT is to develop and promote research activities to solve challenges
and stimulate socio-economic development in a manner that will benefit Quebec and other nations. In doing so, the FRQNT prioritizes interdisciplinary international collaboration, research partnerships, and diversity in its approaches.
Samuel is a distinguished leader at the intersection of research, business development, and clinical care in the Canadian health and life sciences sector. With more than 15 years of service at the BC Cancer Agency and the BC Provincial Health Services Authority, he has held senior executive roles in research, strategic relationships, and business development.
Dr. Abraham has also served as a Strategic Advisor to Western Economic Diversification Canada, supporting initiatives that advanced health research, innovation, and commercialization across Western Canada.
Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.
Kaley is currently a Vice President of Business Development at NanoVation Therapeutics, a Vancouver-based company pioneering in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. Before that Dr. Wilson served as a Principal of Business development at Quark Venture. Investing out of the Global Health Sciences Funds, Dr. Wilson worked closely with Quark’s Investment Committee to identify and diligence potential investment opportunities.
Observer
Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.
Terms of Reference
View Terms of Reference (PDF)